RJA
PJP icon

Raymond James & Associates’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Raymond James & Associates’s Portfolio PJP Stock Details PJP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$569K Sell
6,540
-601
-8% -$51.4K ﹤0.01% 3034
2024
Q2 		$587K Buy
7,141
+254
+4% +$20.2K ﹤0.01% 2969
2024
Q1 		$552K Sell
6,887
-255
-4% -$19.8K ﹤0.01% 3005
2023
Q4 		$543K Sell
7,142
-627
-8% -$44.8K ﹤0.01% 2910
2023
Q3 		$562K Sell
7,769
-69
-0.9% -$5.29K ﹤0.01% 2819
2023
Q2 		$593K Sell
7,838
-198
-2% -$15.1K ﹤0.01% 2825
2023
Q1 		$611K Sell
8,036
-481
-6% -$37.1K ﹤0.01% 2795
2022
Q4 		$669K Sell
8,517
-480
-5% -$36.9K ﹤0.01% 2686
2022
Q3 		$641K Sell
8,997
-39
-0.4% -$2.91K ﹤0.01% 2687
2022
Q2 		$678K Buy
9,036
+43
+0.5% +$3.26K ﹤0.01% 2716
2022
Q1 		$716K Sell
8,993
-191
-2% -$14.8K ﹤0.01% 2834
2021
Q4 		$745K Buy
9,184
+208
+2% +$16.4K ﹤0.01% 2815
2021
Q3 		$694K Buy
8,976
+83
+0.9% +$6.69K ﹤0.01% 2827
2021
Q2 		$716K Buy
8,893
+58
+0.7% +$4.61K ﹤0.01% 2821
2021
Q1 		$697K Buy
8,835
+2,127
+32% +$166K ﹤0.01% 2766
2020
Q4 		$479K Buy
6,708
+3
+0% +$201 ﹤0.01% 2837
2020
Q3 		$428K Sell
6,705
-589
-8% -$38.5K ﹤0.01% 2743
2020
Q2 		$472K Sell
7,294
-22,920
-76% -$1.42M ﹤0.01% 2625
2020
Q1 		$1.66M Sell
30,214
-794
-3% -$48.4K ﹤0.01% 1677
2019
Q4 		$2.01M Sell
31,008
-568
-2% -$34.6K ﹤0.01% 1825
2019
Q3 		$1.79M Sell
31,576
-1,433
-4% -$82.4K ﹤0.01% 1842
2019
Q2 		$1.99M Sell
33,009
-2,028
-6% -$124K ﹤0.01% 1806
2019
Q1 		$2.28M Sell
35,037
-903
-3% -$59.3K ﹤0.01% 1684
2018
Q4 		$2.24M Sell
35,940
-2,321
-6% -$157K ﹤0.01% 1573
2018
Q3 		$2.81M Sell
38,261
-365
-0.9% -$26.2K ﹤0.01% 1596
2018
Q2 		$2.6M Sell
38,626
-1,674
-4% -$108K ﹤0.01% 1603
2018
Q1 		$2.52M Sell
40,300
-4,124
-9% -$272K ﹤0.01% 1568
2017
Q4 		$2.85M Buy
44,424
+708
+2% +$45.4K 0.01% 1458
2017
Q3 		$2.86M Buy
43,716
+519
+1% +$32.8K 0.01% 1397
2017
Q2 		$2.71M Buy
43,197
+92
+0.2% +$5.52K 0.01% 1382
2017
Q1 		$2.53M Sell
43,105
-8,842
-17% -$517K 0.01% 1389
2016
Q4 		$2.91M Sell
51,947
-3,053
-6% -$176K 0.01% 1261
2016
Q3 		$3.39M Sell
55,000
-81
-0.1% -$5.3K 0.01% 1144
2016
Q2 		$3.49M Sell
55,081
-435
-0.8% -$27.4K 0.01% 1034
2016
Q1 		$3.33M Sell
55,516
-33,715
-38% -$2.06M 0.01% 1024
2015
Q4 		$6.24M Sell
89,231
-5,996
-6% -$425K 0.02% 707
2015
Q3 		$6.32M Sell
95,227
-894
-0.9% -$69.6K 0.03% 641
2015
Q2 		$7.53M Buy
96,121
+911
+1% +$70.9K 0.03% 627
2015
Q1 		$7.27M Buy
95,210
+6,821
+8% +$501K 0.03% 575
2014
Q4 		$5.88M Sell
88,389
-2,909
-3% -$194K 0.03% 608
2014
Q3 		$5.81M Sell
91,298
-763
-0.8% -$47.1K 0.03% 559
2014
Q2 		$5.62M Buy
92,061
+2,295
+3% +$133K 0.03% 582
2014
Q1 		$5.08M Sell
89,766
-1,362
-1% -$77.3K 0.03% 560
2013
Q4 		$4.87M Sell
91,128
-3,019
-3% -$151K 0.04% 546
2013
Q3 		$4.33M Sell
94,147
-4,412
-4% -$201K 0.04% 532
2013
Q2 		$4.17M Buy
+98,559
New +$4.1M 0.04% 493

Other funds holding PJP

PAM
Peak Asset Management Louisville, Colorado $567M AUM 16.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
MWM
MGB Wealth Management Addison, Texas $350M AUM 42.75% 1-Year Est. Return

Raymond James & Associates's PJP Position: Q3 2024 in Review

Raymond James & Associates reduced its Invesco Pharmaceuticals ETF (PJP) stake by 8.4% in Q3 2024, selling an estimated $51.4K and leaving 6,540 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #3034.

Raymond James & Associates first reported a position in PJP in Q2 2013 and has held it in 46 quarters since. The position peaked at $7.53M in Q2 2015. 97 funds tracked by Wall St. Rank hold PJP as of Q3 2024.

  • Raymond James & Associates held 6,540 shares of Invesco Pharmaceuticals ETF worth $569K as of Q3 2024.
  • Raymond James & Associates sold 601 Invesco Pharmaceuticals ETF shares in Q3 2024, an estimated $51.4K.
  • Invesco Pharmaceuticals ETF made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3034 holding.
  • Raymond James & Associates first reported a position in Invesco Pharmaceuticals ETF in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Invesco Pharmaceuticals ETF position peaked at $7.53M in Q2 2015.
  • 97 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.